论文部分内容阅读
目的评价恩替卡韦治疗慢性乙型肝炎的早期及远期疗效。方法 56例慢性乙型肝炎患者随机分为治疗组和对照组,治疗组(30例)予恩替卡韦0.5mg/d;对照组(26例)予拉米夫定100mg/d,用药时间最少24周,于第2周、24周时,分别检测血清乙肝病毒载量、e抗原定量及肝功能。结果治疗2周后治疗组HBVDNA定量、e抗原定量、肝功能较对照组明显下降(P<0.01);24周后治疗组HBVDNA阴转率为85.7%,对照组为81.2%,肝功能、e抗原定量治疗组与对照组差异无统计学意义。结论恩替卡韦能快速、强效地抑制乙肝病毒复制,在改善肝脏生化指标、抑制病毒方面均优于拉米夫定。
Objective To evaluate the early and long-term effects of entecavir in the treatment of chronic hepatitis B. Methods Fifty-six patients with chronic hepatitis B were randomly divided into treatment group and control group. The treatment group (30 cases) received entecavir 0.5 mg / d, the control group (26 cases) received lamivudine 100 mg / d for at least 24 weeks At the 2nd and 24th week, serum hepatitis B viral load, e antigen quantitation and liver function were detected. Results After 2 weeks of treatment, the HBVDNA quantification, e antigen quantitation and liver function in the treatment group were significantly lower than those in the control group (P <0.01). After 24 weeks, the negative conversion rate of HBVDNA in the treatment group was 85.7% and in the control group was 81.2% Antigen quantitative treatment group and the control group showed no significant difference. Conclusion Entecavir can inhibit hepatitis B virus replication rapidly and potently, and is superior to lamivudine in improving liver biochemical index and inhibiting virus.